Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

Analysts are calling for 25% top-line growth from Intuitive Surgical this year, to be followed by 15% and 17% revenue growth ...

The stock's fall snapped a three-day winning streak.

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

Vertex Pharmaceuticals secured European approval for Alyftrek, reinforcing its dominance in cystic fibrosis treatment as ...

Vertex Pharmaceuticals is currently pushing against the $467.85 resistance level as its stock maintains an upward trend.

Calidi Biotherapeutics Inc. has spent over 10 years developing a groundbreaking platform for the systemic delivery of genetic medicines that can precisely target tumors. One of the company's core ...

Vertex Pharmaceuticals Inc. closed 10.29% short of its 52-week high of $519.88, which the company achieved on November 8th.

The ASX has fallen 0.31pc by lunchtime in the east, sliding as traders rotate into defensive utilities stocks.

The cell therapy developer, which raised nearly $500 million in 2023 on the promise of its CAR-T work, has floundered since a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Alibaba offers a cheap way to invest in artificial intelligence (AI), cloud computing, digital media, and e-commerce.